Beumer JH, Beijnen JH, Schellens JHM. Mass balance studies, with a focus on
anticancer drugs. Clin Pharmacokinet 2006;45(1):33–58.
Boado RJ, Kang Y-S, Wu D, Pardridge WM. Rapid plasma clearance and metabolism
in vivo of a phosphorothiorate oligodeoxynucleotide with a single, internal
phosphodiester bond. Drug Metab Dispos 1995;23:1297–1300.
Chando TJ, Everett DW, Kahle AD, Starrett AM, Vachharajani N, Shyu WC,
Kripalani KJ, Barbhaiya RH. Biotransformation of irbesartan in man. Drug Metab
Dispos 1998;26:408–417.
Garner RC, Goris I, Laenen AAE, Vanhoutte E, Meuldermans W, Gregory S, Garner
JV, Leong D, Whattam M, Calam A, Snel CAW. Evaluation of accelerator mass
spectrometry in human mass balance and pharmacokinetic study-experience with
(^14) C-labeled (R)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-
chloro phenyl)1-methyl-2(1H)-quinolinone (R115777), a farnesyl transferase inhibi-
tor. Drug Metab and Dispos 2002;30:823–830.
Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed.New York: Marcel Dekker, Inc.;
1982.
Heggie GD, Sommadossi J-P, Cross DS, Huster WJ, Diasio RB. Clinical pharmoki-
netics of 5-fluorouracil and its metabolites in plasma, urine and bile. Cancer Res
1987;47(8):2203–2206.
ICRP Publication 30. Limits for the Intake of Radionuclides by Workers, Part 1. Ann
ICRP 1979;2:3–4.
ICRP Publication 60. Recommendations of the International Commission on
Radiological Protection. 1990.
ICRP Publication 89. Basic Anatomical and Physiological Data for Use in Radiological
Protection: Reference Values. 2003.
Krishna R, Yao M, Srinivas NR, Shah V, Pursley JM, Arnold M, Vacharajani NN.
Disposition of radiolabeled BMS-204352 in rats and dogs. Biopharm Drug Dispos
2002;23:41–46.
Li W, Zhang D, Wang L, Zhang H, Cheng P, Zhang DX, Everett D, Humphreys WG.
Biotransformation of [14C]muraglitazar in male mice. Interspecies differences in
metabolic pathways leading to unique metabolites. Drug Metab Dispos 2006;34:
807–820.
Lu K, Benvenuto JA, Bodey GP, Gottlieb JA, Rosenblum MG, Loo TL.
Pharmacokinetics and metabolism ofb-2^0 -deoxythioguanosine and 6-thioguanine
in man. Cancer Chemother Pharmacol 1982;8(1):119–123.
Lellig H. 1996. European Council Directives. Council Directive 96/29/Euratom: laying
down basic standards for the protection of the health of workers and the general
public against the dangers arising from ionizing radiation. Available athttp://
ec.europa.eu/energy/nuclear/radioprotection/doc/legislation/9629_en.pdf.
Mauthe RJ, Snyderwine EG, Ghoshal A, Freeman SP, Turteltaub KW. Distribution
and metabolism of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in
female rats and their pups at dietary doses. Carcinogenesis 1998;19(5):919–924.
Nuis A. 1997. European Council Directives. Council Directive 97/43/Euratom: on
health protection of individuals against the dangers of ionizing radiation in relation
to medical exposure, and repealing Directive 84/466/Euratom. Available at http://
ec.europa.eu/energy/nuclear/radioprotection/doc/legislation/9743_en.pdf.
REFERENCES 603